Cost-utility analysis of molnupiravir plus usual care versus usual care alone as early treatment for community-based adults with COVID-19 and increased risk of adverse outcomes in the UK PANORAMIC trial
<p><strong>Background </p></strong>The cost-effectiveness of molnupiravir, an oral antiviral for early treatment of SARS-CoV-2, has not been established in vaccinated populations. <p><strong> Aim </p></strong>To evaluate the cost-effectiveness of molnu...
Hlavní autoři: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Další autoři: | |
Médium: | Journal article |
Jazyk: | English |
Vydáno: |
Royal College of General Practitioners
2024
|